<DOC>
	<DOC>NCT00504439</DOC>
	<brief_summary>To assess safety of SB-656933 following repeat dosing for 14 days.</brief_summary>
	<brief_title>A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects.</brief_title>
	<detailed_description>A randomised, double-blind, placebo controlled, dose ascending, parallel group study to evaluate the safety, tolerability, steady state pharmacokinetics and pharmacodynamics of SB-656933-AAA following repeated doses in healthy adult subjects. The pharmacokinetic interaction between repeated doses of SB-656933-AAA and single dose of simvastatin will also be assessed.</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Healthy adult female, aged 1865 years. Female must not be able to have children. Nonsmoking for the last 6 months. Any serious medical condition. Hepatitis B or C and/or HIV positive. Currently on HRT, or other medication except paracetamol. Body Mass Index &gt;30.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>SB-656933,</keyword>
	<keyword>COPD,</keyword>
	<keyword>CXCR2,</keyword>
	<keyword>CD11b,</keyword>
	<keyword>repeat dose,</keyword>
	<keyword>safety,</keyword>
	<keyword>tolerability.</keyword>
</DOC>